



Contact:

Erlinda M. Gordon, M.D.  
Epeius Biotechnologies Corporation  
Tel: 626-441-6695  
egordon@epeiusbiotech.com

**REXIN-G CONTROLS TUMOR GROWTH AND IMPROVES SURVIVAL IN CHEMOTHERAPY-RESISTANT SOFT TISSUE SARCOMA AND OSTEOSARCOMA: PHASE I/II & CONFIRMATORY PHASE II STUDIES**

November 21, 2008, San Marino, California—Epeius Biotechnologies announced today the results of Phase I/II and II studies of Regin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14<sup>th</sup> annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Regin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth.

Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Regin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies. Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Regin-G given as both neoadjuvant and adjuvant monotherapy. These studies indicate that (i) intravenous Regin-G is safe and well-tolerated, and (ii) Regin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

**About Epeius Biotechnologies**

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Regin-G and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at <http://www.epeiusbiotech.com>

XXXXXXXX